Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Radiogenomic correlation of hypoxia-related biomarkers in clear cell renal cell carcinoma.","authors":"Yijun Shao, Harmony S Cen, Anu Dhananjay, S J Pawan, Xiaomeng Lei, Inderbir S Gill, Anishka D'souza, Vinay A Duddalwar","doi":"10.1007/s00432-025-06240-8","DOIUrl":"10.1007/s00432-025-06240-8","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate radiomic models' ability to predict hypoxia-related biomarker expression in clear cell renal cell carcinoma (ccRCC).</p><p><strong>Methods: </strong>Clinical and molecular data from 190 patients were extracted from The Cancer Genome Atlas-Kidney Renal Clear Cell Carcinoma dataset, and corresponding CT imaging data were manually segmented from The Cancer Imaging Archive. A panel of 2,824 radiomic features was analyzed, and robust, high-interscanner-reproducibility features were selected. Gene expression data for 13 hypoxia-related biomarkers were stratified by tumor grade (1/2 vs. 3/4) and stage (I/II vs. III/IV) and analyzed using Wilcoxon rank sum test. Machine learning modeling was conducted using the High-Performance Random Forest (RF) procedure in SAS Enterprise Miner 15.1, with significance at P < 0.05.</p><p><strong>Results: </strong>Descriptive univariate analysis revealed significantly lower expression of several biomarkers in high-grade and late-stage tumors, with KLF6 showing the most notable decrease. The RF model effectively predicted the expression of KLF6, ETS1, and BCL2, as well as PLOD2 and PPARGC1A underexpression. Stratified performance assessment showed improved predictive ability for RORA, BCL2, and KLF6 in high-grade tumors and for ETS1 across grades, with no significant performance difference across grade or stage.</p><p><strong>Conclusion: </strong>The RF model demonstrated modest but significant associations between texture metrics derived from clinical CT scans, such as GLDM and GLCM, and key hypoxia-related biomarkers including KLF6, BCL2, ETS1, and PLOD2. These findings suggest that radiomic analysis could support ccRCC risk stratification and personalized treatment planning by providing non-invasive insights into tumor biology.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"186"},"PeriodicalIF":2.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From controversy to clarity: reimagining the role of CDK4/6 inhibitors in the adjuvant setting- a number needed to treat perspective.","authors":"Armando Orlandi","doi":"10.1007/s00432-025-06229-3","DOIUrl":"10.1007/s00432-025-06229-3","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"185"},"PeriodicalIF":2.7,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody.","authors":"Yuki Majima, David Kryza, Mitsuaki Sanada, Jacqueline Sidi-Boumedine, Patrick Mehlen, Benjamin Gibert, Jean-Yves Blay, Fumiyoshi Okano","doi":"10.1007/s00432-025-06236-4","DOIUrl":"10.1007/s00432-025-06236-4","url":null,"abstract":"<p><strong>Purpose: </strong>Tumor imaging or therapy using cancer specific carriers combined with a radioisotope has huge potential. In radiopharmaceutical development, it is important to ensure target specificity and minimal binding to normal tissues for both tumor detection and treatment. In previous studies, we identified CAPRIN-1 as a cancer-specific antigen, which is widely expressed on the cell surface membrane in many types of solid cancers, and created TRK-950, a humanized monoclonal antibody raised against CAPRIN-1, followed by conducting clinical development. In this proof-of-concept study, we prepared radiolabeled form of TRK-950 and investigated their potential as tumor imaging or therapeutic agents.</p><p><strong>Methods: </strong>An [¹¹¹In]In-DOTA-TRK-950 was prepared and administered to tumor-bearing mice, and its tumor accumulation and pharmacokinetics were evaluated with SPECT/CT imaging. Next, the anti-tumor effect of a [¹⁷⁷Lu]Lu-DOTA-TRK-950 was evaluated. Additionally, radiolabeled TRK-950-F(ab')₂, an antibody fragment of TRK-950, was similarly evaluated for their potential.</p><p><strong>Results: </strong>At 72 h after administration of [¹¹¹In]In-DOTA-TRK-950, tumor accumulation was high at 24.8% IA/g for 4T1 and 18.9% IA/g for HT-29, both of which are CAPRIN-1-high cancer cells, while tumor accumulation remained low at 7.5% IA/g for MNNG/HOS, which are CAPRIN-1-low cancer cells. Regarding therapeutic evaluations, strong anti-tumor effects and prolonged survival were observed after administration of [¹⁷⁷Lu]Lu-DOTA-TRK-950 to 4T1 and HT-29 tumor-bearing mice. Furthermore, these results were also observed in the 4T1 tumor-bearing model with radiolabeled TRK-950-F(ab')₂, which has shorter pharmacokinetics.</p><p><strong>Conclusion: </strong>This study demonstrates that radiopharmaceuticals targeting CAPRIN-1, including radiolabeled TRK-950 and TRK-950-F(ab')₂, have high potential as radiopharmaceuticals.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"184"},"PeriodicalIF":2.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter arterial infusion chemotherapy combined with lipiodol chemoembolization for advanced gastric fundus and cardia cancer with obstruction.","authors":"Jiajia Zhang, Gang Zhou, Meipan Yin, Yishu Ma, Wei He, Yonghua Bi, Gang Wu","doi":"10.1007/s00432-025-06169-y","DOIUrl":"10.1007/s00432-025-06169-y","url":null,"abstract":"<p><strong>Purpose: </strong>Gastric fundus and cardia cancer are increasingly common, diagnosed at a late stage, often with severe obstruction, and have a poor prognosis. Transcatheter arterial lipiodol chemoembolization (TACE) is rarely used for gastric cancer. This single-center retrospective study aimed to analyze the efficacy and safety of transcatheter arterial infusion chemotherapy (TAI) combined with TACE in advanced gastric fundus and cardia cancer with obstruction and compare it to bland embolization (BE).</p><p><strong>Materials and methods: </strong>The clinical efficacy of TAI-TACE was evaluated through technical and clinical success rates, obstruction relief, tumor response, overall survival (OS), and postoperative adverse events. TAI-TACE and TAI-BE efficacies were compared.</p><p><strong>Results: </strong>The study included 53 patients (age 70.0 ± 11.1 years, 38 males). Thirty-two patients underwent TAI-TACE, and 21 underwent TAI-BE. The cohort's technical success rate was 100%. The pre- and post-intervention median Stooler grades were 4 and 2 in the TAI-TACE group and 3 and 3 in the TAI-BE group, respectively. Compared to the TAI-BE group, the TAI-TACE group had a higher clinical success rate (78.1%, 25/32 vs. 42.9%, 9/21; P = 0.009), a better objective response rate (53.1% vs. 38.1%; P = 0.016), and a longer median OS (13.0; 95% confidence interval (CI), 3.2-22.8 vs. 10.0; 95% CI, 8.5-11.5; P = 0.039) months. All adverse events were grade 1.</p><p><strong>Conclusion: </strong>The TAI-TACE interventional therapy scheme was safe and effective, achieving rapid tumor shrinkage, obstructive symptom alleviation, improved quality of life, and a significantly better overall effect than TAI-BE.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"183"},"PeriodicalIF":2.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, therapeutic and prognostic differences between male and female patients with breast cancer-a comparison of 2510 men and 307,634 women in a registry-based study in Germany.","authors":"Marion Graf, Michael Gerken, Monika Klinkhammer-Schalke, Simone Schrodi, Armin Pauer, Karla Geiss, Olaf Ortmann, Elisabeth C Sturm-Inwald","doi":"10.1007/s00432-025-06220-y","DOIUrl":"10.1007/s00432-025-06220-y","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of the present study was to compare patient, tumor characteristics and prognostic factors as well as diagnostics and therapies between men and women with breast cancer. The rates of primary distant metastases, contralateral second tumors, overall survival (OS), recurrence, and recurrence-free survival (RFS) were analyzed and compared between men and women.</p><p><strong>Methods: </strong>This retrospective cohort study included patient data from 18 clinical cancer registries in Germany (2000-2018). Differences in risk factors and short-term endpoints were analyzed via univariable and multivariable binary logistic regression analyses. OS, RFS, and the rate of subsequent second tumors were examined via Kaplan‒Meier, univariable and multivariable Cox regression methods.</p><p><strong>Results: </strong>Compared with women, male patients with breast cancer presented a significantly greater risk of unfavorable prognostic factors, such as advanced stage, lymphatic invasion, and more primary distant metastases. While sentinel lymph node biopsy and HER-2 testing were comparable, treatment rates for men were 9.5-29.0% lower than those for women. In multivariable analyses, men had a 1.32-fold increased risk of death (95% CI 1.24-1.41; p < 0.001). The risk of recurrence/mortality was significantly increased by a factor of 1.531 (95% CI 1.43-1.65; p < 0.001). Adjustment for therapy in a multivariable regression model did not significantly affect the risk of death. Nevertheless, men had a survival benefit from systemic therapies comparable to that of women.</p><p><strong>Conclusion: </strong>Neither patient and tumor characteristics nor differences in therapy could completely explain the difference in mortality between men and women. Differences in lifestyle or biological factors could play a role.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"181"},"PeriodicalIF":2.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients.","authors":"Xueqin Zhao, Wei Fu","doi":"10.1007/s00432-025-06207-9","DOIUrl":"10.1007/s00432-025-06207-9","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to characterize SMARCA4-deficient tumors using ¹⁸F-FDG PET/CT and explore its role in diagnosis, staging, therapeutic response assessment, and prognosis across multiple pathological subtypes.</p><p><strong>Methods: </strong>We retrospectively analyzed four patients with histologically confirmed SMARCA4-deficient tumors. Clinical features, ¹⁸F-FDG PET/CT findings, pathological subtypes, molecular characteristics, treatment modalities, and outcomes were evaluated.</p><p><strong>Results: </strong>All tumors demonstrated high FDG uptake, indicating elevated metabolic activity. Imaging patterns varied by subtype, including undifferentiated carcinoma and non-small cell lung cancer. Treatment strategies involved chemotherapy, immunotherapy, and targeted therapy with diverse responses. SMARCA4 deficiency was associated with poor prognosis and potential treatment resistance.</p><p><strong>Conclusion: </strong>¹⁸F-FDG PET/CT is valuable in the comprehensive assessment of SMARCA4-deficient tumors. Combined with molecular profiling, it enhances diagnostic accuracy and aids in individualized treatment planning. This case series offers preliminary guidance for clinicians managing this rare, aggressive tumor type.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"182"},"PeriodicalIF":2.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12133917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prognostic PET radiomic model for risk stratification in non-small cell lung cancer: integrating radiogenomics and clinical features to predict survival and uncover tumor biology insights.","authors":"Parisa Taheri, Aaron Golden","doi":"10.1007/s00432-025-06232-8","DOIUrl":"10.1007/s00432-025-06232-8","url":null,"abstract":"<p><strong>Purpose: </strong>To develop a survival risk score using ¹⁸F-FDG PET radiomic features for non-small cell lung cancer (NSCLC) patients and to evaluate its biological basis as a prognostic radiomic signature through radiogenomic analyses.</p><p><strong>Methods: </strong>We utilized several NSCLC cohort datasets from the Cancer Imaging Archive (TCIA) for radiomic analysis, where transcriptomics data were available through the Cancer Genome Atlas (TCGA). A total of 945 radiomic features were extracted from the segmented tumors. A survival-based radiomic model was developed, from which a radiomic risk score was calculated. Radiogenomic analyses were then performed to explore correlations between radiomic risk cohorts and tumor transcriptomics, oncogenic pathways, and genetic mutations. We also constructed a nomogram by combining clinical and radiomic risk factors.</p><p><strong>Results: </strong>The PET-radiomic model significantly predicted the 5-year survival rate of patients, with AUCs of 0.78, 0.71, and 0.73 in the training, validation, and testing cohorts, respectively. Integration of clinical features and the radiomic risk score in a nomogram demonstrated enhanced efficacy, achieving AUCs greater than 0.85. Radiogenomic analysis revealed that while the low-risk group indicated anti-tumor immunity, the high-risk group exhibited transcriptomic characteristics associated with enhanced tumor aggressiveness, with consistent correlations between risk group membership, oncogenic pathways, immune cell types, and critical gene alterations.</p><p><strong>Conclusion: </strong>PET-radiomic features successfully delineated high- and low-risk NSCLC patient groups. Supporting radiogenomic analysis identified tumor-promoting characteristics and immune-suppressing activity in the high-risk group, which is consistent with these patients' prognoses.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"180"},"PeriodicalIF":2.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited survival benefit in patients diagnosed with glioblastoma post-2016: a SEER population based registry analysis.","authors":"Shaurya Dhingra, Matthew Koshy, Mark Korpics","doi":"10.1007/s00432-025-06171-4","DOIUrl":"10.1007/s00432-025-06171-4","url":null,"abstract":"<p><strong>Background: </strong>The EF14 clinical trial reported an improvement in median overall survival (OS) from 16.0 months to 20.9 months in patients with glioblastoma (GBM) who received treatment with tumor treating fields (TTFs). This study evaluates overall survival in a large population-based cohort of patients with GBM before and after FDA approval of TTFs in 2015.</p><p><strong>Methods: </strong>A total of 27,534 patients from the Surveillance, Epidemiology and End Results (SEER) database with GBM who underwent surgery and post-operative radiotherapy were grouped into three diagnosis periods: those diagnosed pre-temozolomide (2000-2004), those diagnosed post-temozolomide (2005-2015), and those diagnosed post-TTFs (2016-2020). Overall survival (OS) was calculated using the Kaplan-Meier method, and multivariate Cox regression models were employed to estimate hazard ratios (HR).</p><p><strong>Results: </strong>GBM diagnosis in the post-TTFs period was associated with a median OS of 15 months (95% CI 14-15 months) compared to a median OS of 14 months (95% CI 14-14 months, p < 0.001) for GBM diagnosis in the post-temozolomide/pre-TTFs period. 24-months OS was 25.6% (95% CI 24.5-26.8%) in the post-TTFs period and 24.7% (95% CI 24.0-25.4%) in the post-temozolomide/pre-TTFs period. In a multivariate model accounting for clinical characteristics, diagnosis in the post-TTFs period as compared to the post-temozolomide/pre-TTFs period was significantly associated with OS (HR: 0.941, 95% CI 0.912-0.972, p < 0.001).</p><p><strong>Conclusion: </strong>This population-based cohort demonstrated minimal change in survival for patients diagnosed with GBM before and after FDA approval of TTFs in 2015.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"179"},"PeriodicalIF":2.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiome in prostate cancer: pathogenic mechanisms, multi-omics diagnostics, and synergistic therapies.","authors":"Chengran Wang, Tianqi Dong, Xin'ao Rong, Yuce Yang, Jianhui Mou, Jiaqi Li, Jianli Ge, Xupeng Mu, Jinlan Jiang","doi":"10.1007/s00432-025-06187-w","DOIUrl":"10.1007/s00432-025-06187-w","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is a leading cause of cancer-related deaths in men, with the microbiome emerging as a significant factor in its development and progression. Understanding the microbiome's role could provide new insights into PCa pathogenesis and treatment.</p><p><strong>Objective: </strong>This review aims to explore the interactions between the microbiome and PCa, focusing on microbial imbalances and their effects on immune responses, inflammation, and hormone levels. It also discusses advanced research techniques and the potential for microbiome modulation in PCa management.</p><p><strong>Methods: </strong>The review synthesizes current literature on the microbiome's role in PCa, highlighting differences in microbial composition between cancerous and healthy prostate tissues. It examines techniques such as high-throughput sequencing and metagenomics and explores the mechanisms through which the microbiome influences PCa.</p><p><strong>Conclusions: </strong>The review reveals substantial microbial differences in prostate tissues of PCa patients compared to healthy individuals, indicating a potential link between microbiome alterations and disease progression. It highlights the promise of microbiome-based strategies for diagnosis and treatment and underscores the need for further research into personalized, microbiome-centric approaches for PCa management.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"178"},"PeriodicalIF":2.7,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life after risk reducing mastectomy in a Portuguese cohort of BRCA pathogenic/likely pathogenic variant carriers.","authors":"Maria Raposo, Bárbara Peleteiro, André Magalhães, Sandra Torres, Inês Insua-Pereira, Raquel Guimarães, Luzia Garrido, Susy Costa, José Luis Fougo","doi":"10.1007/s00432-025-06231-9","DOIUrl":"10.1007/s00432-025-06231-9","url":null,"abstract":"<p><strong>Purpose: </strong>Women with pathogenic/likely pathogenic (P/LP) variants in BRCA1/2 genes have an increased lifetime risk of breast and ovarian cancer. Cancer risk management options include intensive breast surveillance (IBS) and risk reducing mastectomy (RRM). This study aims to compare the effect of these strategies on quality of life, anxiety, and depression to enhance shared decision-making.</p><p><strong>Methods: </strong>We retrospectively analysed clinical records of 221 women with P/LP variants in BRCA1/2 genes, from 2007 to 2024. A total of 169 questionnaires containing Hospital Anxiety and Depression Scale (HADS) and BREAST-Q were sent, from May to September 2024. Ninety-nine women, 48 who had undergone RRM and 51 who had opted for IBS, completed the questionnaires. Patient-reported outcome measures (PROMs) were compared based on their choice.</p><p><strong>Results: </strong>Significant differences were found in age at genetic testing and personal history of breast cancer between the groups. In BREAST-Q, the IBS group reported higher scores, with statistically significant differences for Satisfaction with Breasts and Physical Well-Being: Chest. These differences were only observed in the group of women without personal breast cancer history who underwent RRM.</p><p><strong>Conclusions: </strong>No significant differences were found in psychologic distress levels between the IBS and RRM group. Although RRM is an effective method for reducing breast cancer risk in women with P/LP variants in BRCA1/2 genes, carriers should be informed of its impact on quality of life. Notably, once a woman is diagnosed with breast cancer, these differences lose effect.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"177"},"PeriodicalIF":2.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}